Genetic: Genetic Testing

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia1
89Lymphangioleiomyomatosis1
90Retinitis pigmentosa1
IDDisease name (Link within this page)Number of trials
158Tuberous sclerosis1
299Cystic fibrosis1

79. Homozygous familial hypercholesterolemia


Clinical trials : 525 / Drugs : 330 - (DrugBank : 49) / Drug target genes : 20 - Drug target pathways : 59 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

89. Lymphangioleiomyomatosis


Clinical trials : 44 / Drugs : 54 - (DrugBank : 19) / Drug target genes : 27 - Drug target pathways : 143 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

90. Retinitis pigmentosa


Clinical trials : 203 / Drugs : 267 - (DrugBank : 49) / Drug target genes : 55 - Drug target pathways : 162 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

158. Tuberous sclerosis


Clinical trials : 132 / Drugs : 91 - (DrugBank : 22) / Drug target genes : 41 - Drug target pathways : 119 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,885 / Drugs : 1,782 - (DrugBank : 252) / Drug target genes : 110 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries